Skip to content

A Clinical trial on SEENTHIL CHOORANAM in the management of UTHIRAVATHASURONITHAM (Rheumatoid arthritis).

A Prospective Open labelled non randomized phase II clinical trial on Uthiravathasuronitham with trial drug Seenthil Choornam.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031274
Enrollment
40
Registered
2021-02-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

Intervention1: SEENTHIL CHOORANAM: 1.5 gm twice a day orally for 45 days Control Intervention1: NIL: NIL

Sponsors

Government Siddha Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.SIDDHA ASPECT:- Positive findings in Uyirthathu Udalthathu, Envagai Thervu. 2.MODERN ASPECT:- RA factor test-positive Anti ccp test- Positive CRP ANA test

Exclusion criteria

Exclusion criteria: 1.Other degenerating joint diseases-osteoarthritis sero negative spondyloarthritis, ankylosing spondylitis. 2.Infectious joint diseases like Tuberculosis , Chronic polyarthritis in chickungunia viral infection. 3.Metabolic joint disease like Gout. 4.Pregnancy and lactating mother. 5.Chronic liver and renal disease patients. 6.People with RA factor negative.

Design outcomes

Primary

MeasureTime frame
1.Symptomatic relief - reduction in pain, swelling, movement difficulties. 2. Improve the physical movements and relieve the disabilities and structural defects of hands and legs as much as possible. 3.Reduce any extra articular involvement of the disease if any.Timepoint: 45 days

Secondary

MeasureTime frame
1.Prevent recurrence of the disease by advising ,continuous and periodic intake of medicine and dietary regimen. 2. Proper monitoring of patients and disease state with relevant blood test and immunological assays.Timepoint: 45 days

Countries

India

Contacts

Public ContactDr Manoharan MDS PhD

Government Siddha Medical College and Hospital

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026